| sess_SDA-2026-04-13- | The authors explicitly state that the effects of these novel genes (MATR3, CHCHD | 0.71 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-165527-8256a071 |
| sess_SDA-2026-04-13- | The debate proposed K280 acetylation creates a β-sheet nucleation interface but | 0.86 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-debate-20260412-094556-86f36bb3 |
| sess_SDA-2026-04-13- | The debate proposed K280 acetylation creates a β-sheet nucleation interface but | 0.74 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-debate-20260412-094556-86f36bb3 |
| sess_SDA-2026-04-13- | The debate outlined peripheral immune involvement but failed to address the prec | 0.78 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-debate-20260411-064946-4940f331 |
| sess_SDA-2026-04-13- | The debate outlined peripheral immune involvement but failed to address the prec | 0.67 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-debate-20260411-064946-4940f331 |
| sess_SDA-2026-04-13- | The abstract reports extraordinary dopamine increases (>500-fold in drug-free pa | 0.67 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-145531-5c4e7b59 |
| sess_SDA-2026-04-13- | The study shows homozygous R136S fully rescues APOE4-driven pathology while hete | 0.81 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-145358-185db2c8 |
| sess_SDA-2026-04-13- | The abstract shows microglia ameliorate OxPC toxicity to neurons and oligodendro | 0.68 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-165345-41805e1b |
| sess_SDA-2026-04-13- | The abstract shows microglia ameliorate OxPC toxicity to neurons and oligodendro | 0.62 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-165345-41805e1b |
| sess_SDA-2026-04-13- | The abstract shows microglia ameliorate OxPC toxicity to neurons and oligodendro | 0.92 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-165345-41805e1b |
| sess_SDA-2026-04-13- | Despite FDA warnings and a 315% increased erythrocytosis risk with TRT, the asso | 0.83 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-155308-2c6815fb |
| sess_SDA-2026-04-13- | The study shows that MCT1 disruption leads to axon degeneration and neuron death | 0.78 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-170325-196c7ee5 |
| sess_SDA-2026-04-13- | The study shows that MCT1 disruption leads to axon degeneration and neuron death | 0.82 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-170325-196c7ee5 |
| sess_SDA-2026-04-13- | The study shows VCP-mutant astrocytes exhibit hypoxia response activation withou | 0.78 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88 |
| sess_SDA-2026-04-13- | This study identifies oligodendrocytes as drivers of neuroinflammation in PD, co | 0.79 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9 |
| sess_SDA-2026-04-13- | The title suggests B cells actively maintain tolerance to AQP4, but the specific | 0.66 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-142329-c1db787b |
| sess_SDA-2026-04-13- | How does PIKFYVE inhibition activate unconventional protein clearance via exocyt | 0.63 | 0 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-143119-8ae42941 |
| sess_SDA-2026-04-13- | The title suggests B cells actively maintain tolerance to AQP4, but the specific | 0.79 | 3 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-142329-c1db787b |
| sess_SDA-2026-04-13- | While the study shows HDAC1/2 deletion improves amyloid clearance and cognition, | 0.95 | 7 | 4 | completed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-110327-26e1d6c7 |
| sess_SDA-2026-04-13- | The debate highlighted promising PTMs like K280 acetylation and O-GlcNAcylation | 0.65 | 0 | 4 | completed | 2026-04-13 | SDA-2026-04-13-gap-debate-20260412-094612-a2e3bd09 |
| sess_SDA-2026-04-13- | RNA binding protein dysregulation across ALS FTD AD | 0.50 | 0 | 4 | completed | 2026-04-13 | SDA-2026-04-13-gap-20260410-172514 |
| sess_SDA-2026-04-12- | The debate highlighted BBB penetration as a major hurdle for SPM therapeutics bu | 0.66 | 0 | 4 | completed | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113110-2059f65f |
| sess_SDA-2026-04-04- | The provided transcript contains only speaker labels [Theorist] and [Synthesizer | 0.95 | 7 | 4 | completed | 2026-04-13 | SDA-2026-04-04-gap-debate-20260403-222510-20260402 |
| sess_SDA-2026-04-12- | The debate highlighted a critical dosing paradox where both hypo- and hypermethy | 0.82 | 3 | 4 | completed | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113051-5dce7651 |
| sess_SDA-2026-04-12- | The debate revealed conflicting evidence about whether connexin-43 mediates mito | 0.74 | 3 | 4 | completed | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113038-57244485 |
| sess_SDA-2026-04-12- | The abstract suggests that Aβ-tau synergy could explain negative results from an | 0.70 | 3 | 4 | completed | 2026-04-13 | SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974 |
| sess_SDA-2026-04-12- | The abstract explicitly questions whether AD's hallmark pathologies induce choli | 0.79 | 3 | 4 | completed | 2026-04-13 | SDA-2026-04-12-20260411-082446-2c1c9e2d |
| sess_SDA-2026-04-12- | The debate identified a critical mechanistic gap between SCFA production by gut | 0.70 | 3 | 4 | completed | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113021-6fbc6da4 |
| sess_SDA-2026-04-04- | How do neurodegeneration gene expression patterns in SEA-AD differ from other po | 0.70 | 3 | 4 | completed | 2026-04-13 | SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222549-202 |
| sess_SDA-2026-04-12- | How does APOE4's beneficial immune function reconcile with its established role | 0.78 | 3 | 4 | completed | 2026-04-13 | SDA-2026-04-12-gap-pubmed-20260410-184126-b2c3e2e8 |
| sess_SDA-2026-04-04- | Which metabolic biomarkers can distinguish therapeutic response from disease pro | 0.77 | 3 | 4 | completed | 2026-04-13 | SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222618-c69 |
| sess_SDA-2026-04-12- | Why have numerous phase 3 clinical trials failed despite advances in understandi | 0.67 | 3 | 5 | completed | 2026-04-12 | SDA-2026-04-12-gap-debate-20260410-145418-c1527e7b |
| sess_SDA-2026-04-04- | How do astrocyte-neuron metabolic interactions change during disease progression | 0.86 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222618-e6a |
| sess_SDA-2026-04-04- | What are the critical protein expression changes and post-translational modifica | 0.68 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-frontier-proteomics-1c3dba72 |
| sess_SDA-2026-04-04- | How do peripheral immune system alterations influence CNS pathology and neurodeg | 0.76 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-frontier-immunomics-e6f97b29 |
| sess_SDA-2026-04-04- | How do peripheral immune system alterations influence CNS pathology and neurodeg | 0.78 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-frontier-immunomics-e6f97b29 |
| sess_SDA-2026-04-04- | How do structural and functional connectivity changes in the human brain connect | 0.71 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-frontier-connectomics-84acb35a |
| sess_SDA-2026-04-09- | The debate mentioned tau PTM targeting but did not identify which modifications | 0.84 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| sess_SDA-2026-04-09- | The debate mentioned tau PTM targeting but did not identify which modifications | 0.71 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| sess_SDA-2026-04-04- | Investigate prion-like spreading of tau pathology through connected brain region | 0.90 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| sess_sda-2026-04-01- | Mitochondrial transfer between neurons and glia? | 0.71 | 3 | 4 | completed | 2026-04-12 | sda-2026-04-01-gap-20260401231108 |
| sess_sda-2026-04-01- | Protein aggregation cross-seeding across neurodegenerative diseases? | 0.70 | 3 | 4 | completed | 2026-04-12 | sda-2026-04-01-gap-9137255b |
| sess_sda-2026-04-12- | Which EV-derived biomarkers (phospho-tau, amyloid-beta, synaptic proteins, infla | 0.75 | 3 | 4 | completed | 2026-04-12 | sda-2026-04-12-ev-ad-biomarkers |
| sess_sda-2026-04-01- | PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns | 0.69 | 3 | 4 | completed | 2026-04-12 | sda-2026-04-01-gap-005 |
| sess_sda-2026-04-01- | RNA binding protein dysregulation across ALS FTD and AD | 0.72 | 3 | 4 | completed | 2026-04-12 | sda-2026-04-01-gap-v2-68d9c9c1 |
| sess_SDA-2026-04-12- | Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn | 0.84 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-12-gap-debate-20260410-112927-b4535f82 |
| sess_SDA-2026-04-04- | How does microglial priming contribute to early Alzheimer's disease pathology? F | 0.80 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| sess_SDA-2026-04-04- | Investigate mechanistic links between early microglial priming states, neuroinfl | 0.86 | 4 | 4 | completed | 2026-04-12 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| sess_SDA-2026-04-04- | Investigate mechanistic links between early microglial priming states, neuroinfl | 0.95 | 7 | 5 | completed | 2026-04-12 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| sess_SDA-2026-04-12- | What is the actual quantitative contribution of FcRn-mediated transcytosis to BB | 0.91 | 7 | 6 | completed | 2026-04-12 | SDA-2026-04-12-gap-debate-20260410-112908-13c403ee |